WeedMD (TSXV:WMD) announced it will absorb the cost of the excise tax on medical cannabis imposed by the Canadian government.

As quoted in the press release:

Given the recent government announcements to impose an excise tax of $1 per gram (or 10 [percent] of the sale price) on cannabis (the “Excise Tax”), WeedMD is pleased to announce it will further support its medical-use customers by continuing to offer competitive pricing on its premium, medical-grade cannabis and that it will absorb the increased cost as a result of the Excise Tax. Scheduled to come into effect on October 17, 2018, the Excise Tax is applicable for both the recreational and the medical market on all cannabis products containing [tetrahydrocannabinol] THC.

Additionally, effective immediately, the Company will be offering free standard shipping on all medical cannabis orders with no minimums and no restrictions. WeedMD also remains committed to its compassionate pricing program which supports patients that require financial assistance.

“Despite the fact that almost all prescription drugs are tax free in Canada, medical cannabis patients are being forced to pay the Excise Tax on their medicine. WeedMD is proud to demonstrate support for our patients by implementing these cost-relief initiatives and putting our patients first,” said Keith Merker, CEO of WeedMD. “The reality is that many patients do not have the cost of their medicine covered by insurance and often struggle to afford their prescriptions. Adding an additional tax could put their treatment further out of reach.”

Click here to read the full press release.

Source: globenewswire.com


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that it has been issued a Cease Trade Order (“ CTO ”) by the Ontario Securities Commission (the “ OSC ”) as it no longer expects to file the following periodic disclosure documents (collectively, the “ Documents ”) by June 11, 2021, as previously disclosed:

Keep reading... Show less

Adds two accomplished female directors to the Board

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the results of its Annual and Special Meeting of Shareholders held on June 10, 2021 (the “Meeting”). Each of the eight individuals nominated for election as a director of Trulieve at the Meeting were elected, including new nominees, Giannella Alvarez and Jane Morreau .

Keep reading... Show less

The National Football League (NFL) wants to know more about cannabis as a pain reliever, and it’s willing to put up an initial US$1 million for research.

Also this week, a cannabis operator announced plans to buy assets from a languishing producer.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 89th nationwide.

The dispensary will be located next to the Citrus Park Town Center and helps meet Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The facility joins four other Tampa dispensaries, as well as several more in nearby Clearwater , St. Petersburg , and Largo.

Keep reading... Show less

On June 10, 2021, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (the “Issuer”) (CSE: GTII) (OTCQX: GTBIF), sold 1,666,667 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of US$30.00 per share in a private transaction.

“This transaction brings Green Thumb a new institutional shareholder who is aligned with management’s long-term vision,” said Manager of RCP23 Benjamin Kovler.  “RCP23 has historically sold shares on behalf of our legacy shareholders who invested prior to Green Thumb going public.”

Keep reading... Show less